We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKibo Energy Regulatory News (KIBO)

Share Price Information for Kibo Energy (KIBO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0375
Bid: 0.035
Ask: 0.04
Change: 0.00 (0.00%)
Spread: 0.005 (14.286%)
Open: 0.0425
High: 0.0425
Low: 0.0375
Prev. Close: 0.0375
KIBO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kibo Subsidiary Announces Update of JVA

1 Dec 2023 07:00

RNS Number : 2994V
Kibo Energy PLC
01 December 2023
 

Kibo Energy PLC (Incorporated in Ireland)

(Registration Number: 451931)

(External registration number: 2011/007371/10)

LEI Code: 635400WTCRIZB6TVGZ23

Share code on the JSE Limited: KBO

Share code on the AIM: KIBO

ISIN: IE00B97C0C31

('Kibo' or 'the Company')

 

Dated: 1 December 2023

 

Kibo Energy PLC ('Kibo' or the 'Company')

 

Kibo Subsidiary Announces Update of Joint Venture Agreement

 

Kibo Energy PLC (AIM: KIBO; AltX: KBO), the renewable energy-focused development company, announces that further to its previous announcements dated 23 October 2023 and 13 November 2023, respectively, its subsidiary Mast Energy Developments PLC ('MED'), a UK-based multi-asset owner, developer and operator in the rapidly growing flexible market, announces that, under the terms of the binding Joint Venture Agreement (JVA'), Proventure Holdings (UK) Ltd, part of the Proventure Group ('Proventure'), has failed to meet the conditions to complete the transaction by the contractually agreed completion long-stop date of 30 November 2023.

 

Under the terms of the JVA, Proventure is required to make an initial interim payment of £2m (the 'Interim Payment') as well as payment of the balance of the investment due of c. £3.9m to the Joint Venture Special Purpose Vehicle ('SPV'). Unless or until the JVA has been completed, Proventure remains contractually bound under the JVA, and remains in breach of its obligations thereto. As a result of Proventure not performing, MED has given Proventure formal notice of enforcement and Proventure now has seven (7) days to remedy the position. If Proventure fails to do so within the remedial timeline, MED will consider all its available options, including, but not limited to, terminating the JVA save for MED's right to claim damages and costs, commencing proceedings against Proventure and affected parties as well as alternative investment opportunities. MED has furthermore made the decision to grant no further extensions with respect to the deadline for the completion of the JV.

 

As announced in the Company RNS dated 13 November 2023, MED provided an extension in respect of the Interim Payment deadline and Proventure has thus incurred a total late payment penalty amounting to £60,000 as well as liquidated damages of 0.25% of the total investment balance due plus any additional costs and expenses incurred by MED in respect of the JV projects, all of which are due and payable by Proventure to MED. Under the terms of the JVA, in addition to the foregoing penalties, should the JVA be terminated, Proventure shall furthermore pay to MED liquidated damages as a sum equal to 5% of the total investment value due and any reasonable costs and expenses incurred by MED in connection with the agreement.

 

In consideration of the delays, MED has proceeded with advanced discussions with an alternative institutional investor to secure the necessary funding required to advance MED's development plans.

 

Further details can be found in the full MED announcement, which is available below and at med.energy:

 

 

-------------------------

Dated: 01 December 2023

 

Mast Energy Developments PLC ('MED' or 'the Company')

 

MED Binding Joint Venture Agreement Completion Update

 

Mast Energy Developments PLC, the UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market, announces that further to its previous announcements dated 23 October 2023 and 13 November 2023 respectively, under the terms of the binding JVA, Proventure is required to make an initial interim payment of £2m (the 'Interim Payment') as well as payment of the balance of the investment of c. £3.9m to the Joint Venture SPV, in order to complete the transaction by the contractually agreed completion long-stop date of 30 November 2023.

 

Proventure has not met the abovementioned conditions under the JVA and unless or until the JVA has been completed, Proventure remains contractually bound under the JVA and is yet to perform its obligations thereof. As a result of Proventure not performing such obligations, MED has given Proventure formal notice of enforcement and Proventure now has seven (7) days to remedy the position. If Proventure fails to do so within the remedial timeline, MED will consider all its available options, including, but not limited to, terminating the JVA save for MED's right to claim damages and costs, commencing proceedings against Proventure and associated parties, as well as alternative investment opportunities.

 

In consideration for MED previously granting an extension in respect of the Interim Payment deadline, as set out in our announcement dated 13 November 2023, Proventure has incurred a total late payment penalty amounting to £60,000 as well as liquidated damages of 0.25% of the total investment balance due, plus any additional costs and expenses incurred by MED in respect of the JV projects, all of which are due and payable by Proventure to MED unless waived in part or in full by MED. Under the terms of the JVA, in addition to the foregoing penalties, in the event that the JVA is terminated, Proventure shall pay to MED liquidated damages being a sum equal to 5% of the total investment value due, plus any reasonable costs and expenses incurred by MED in connection with the agreement. All of the foregoing penalties exclude MED's right to claim further damages as a result of the breach and potential misrepresentation by Proventure.

 

Further, MED is in advanced discussions with an alternative institutional investor in order to secure the necessary funding required to advance MED's development plans, should Proventure fail to remedy the position referred to above. In the meantime, MED is in the process of also assessing various short-term funding options in order to ensure that the Company can meet its ongoing working capital requirements.

 

Moreover, MED has decided to put its Pyebridge 9MW flexible power generation asset (the 'Site') into care and maintenance, in preparation for a significant overhaul work programme planned for the Site's reciprocal generation engines, pending the necessary funding. The planned work programme will result in the Site reaching its full generation, efficiency and profitability potential. Until such time that the work programme has been completed, no further revenue from the Site is expected.

 

Pieter Krügel, MED CEO, commented: "We are, of course, very disappointed with Proventure's continued inability to meet their commitments within the agreed contractual timelines. MED has been working tirelessly to assist and support Proventure and we have done everything we possibly could to ensure successful delivery, however, Proventure's performance is unfortunately outside of MED's control. Based on the latest assurances from Proventure, the MED Board remains cautiously optimistic that Proventure remains fully committed to and should be able to remedy the position within the remedial timeline to pave the way towards building a fruitful partnership with them.

 

"In the meantime, we are engaged in advanced discussions with an alternative institutional investor in order to secure the necessary capex funding to advance MED's development plans should Proventure fail to remedy the position referred to above and we are looking forward to updating the market accordingly."

 

ENDS

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please visit www.med.energy or contact:

 

Pieter Krügel

Info@med.energy

Mast Energy Developments PLC

CEO

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

Zainab Slemang van Rijmenant

zainab@lifacommunications.com

Lifa Communications

Investor & Media Relations Advisor

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulations (EU) no. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this information is now considered to be in the public domain.

 

**ENDS**

 

For further information please visit www.kibo.energy or contact:

 

Louis Coetzee

info@kibo.energy

Kibo Energy PLC

Chief Executive Officer

James Biddle

Roland Cornish

+44 207 628 3396

Beaumont Cornish Limited

Nominated Adviser

Claire Noyce

+44 20 3764 2341

Hybridan LLP

Joint Broker

Damon Heath

+44 207 186 9952

Shard Capital Partners LLP

Joint Broker

Zainab Slemang van Rijmenant

zainab@lifacommunications.com

Lifa Communications

Investor and Media Relations Consultant

 

Johannesburg

1 December 2023

Corporate and Designated Adviser

River Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
JVEFLFFTLDLIVIV
Date   Source Headline
26th Apr 20247:00 amRNSKibo Subsidiary Announces Business Update
23rd Apr 20242:30 pmRNSKibo Subsidiary Announces Major Shareholdings
11th Apr 20247:00 amRNSKibo Subsidiary MAST Announces Business Update
5th Mar 20247:00 amRNSIssue of Shares to Service Provider
4th Mar 202410:45 amRNSKibo Subsidiary Announces TR-1 Notification
28th Feb 20247:00 amRNSMAST New Funding Partner & Proventure Cancellation
21st Feb 20242:46 pmRNSHolding(s) in Company
20th Feb 20241:00 pmRNSKibo Subsidiary Announces TR-1 Notification
9th Feb 202412:45 pmRNSResults of Extraordinary General Meeting
5th Feb 20241:55 pmRNSKibo Subsidiary MAST Announces TR-1 Notification
31st Jan 202410:48 amRNSDirector/PDMR Shareholding
24th Jan 20243:45 pmRNSKibo Subsidiary MAST Announces TR-1 Notification
19th Jan 20241:52 pmRNSPDMR Share Sale
18th Jan 20247:00 amRNSNotice of Extraordinary General Meeting (“EGM”)
16th Jan 202410:50 amRNSCorrection on MED Shareholding
16th Jan 20247:00 amRNSKibo Strategy Update
11th Jan 20247:00 amRNSConversion, Equity Issue, TVR & Board Changes
8th Jan 20247:00 amRNSKibo Subsidiary Announces an Update on JVA
2nd Jan 20247:00 amRNSKibo Subsidiary - Further Update of Payment to JVA
22nd Dec 20237:00 amRNSKibo Subsidiary Announces JVA Completion Update
19th Dec 20232:00 pmRNSPDMR Share Sale
15th Dec 20237:00 amRNSSubsidiary Director Loan & PMDR Share Sale
11th Dec 20238:21 amRNSKibo Subsidiary Update JVA Completion Announcement
11th Dec 20237:00 amRNSMAST: Further Update to the Completion of JVA
7th Dec 20232:15 pmRNSResult of AGM
1st Dec 20237:00 amRNSKibo Subsidiary Announces Update of JVA
15th Nov 20237:00 amRNSNotice of AGM
13th Nov 20237:00 amRNSKibo UK Subsidiary JVA Interim Payment Update
26th Oct 20237:00 amRNSChange of Holding in Mast Energy Developments PLC
23rd Oct 20237:00 amRNSKibo Subsidiary - Update on the Completion of JVA
5th Oct 20237:00 amRNSPartial Settlement of Outstanding Shareholder Loan
4th Oct 20237:00 amRNSSale of Coal Interest in Botswana Power Project
29th Sep 20237:00 amRNSUnaudited Interim Results
22nd Sep 20237:00 amRNSKibo Subsidiary Announces Update on JVA Completion
1st Sep 20237:00 amRNSKibo Subsidiary Announces Further Update on JVA
25th Aug 20237:00 amRNSKibo Subsidiary MED Unaudited Interim Results
16th Aug 202310:10 amRNSClarification on Inaccurate Moneyweb Article
7th Aug 202310:25 amRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSKibo Subsidiary Announces Update on JV Completion
31st Jul 20237:00 amRNSUpdate on MED Definitive and Binding JVA
24th Jul 20234:40 pmRNSTR-1: Notification of major holdings
12th Jul 20231:15 pmRNSKibo Subsidiary Announces Definitive & Binding JVA
3rd Jul 20237:00 amRNSOperational Update: Q2 2023
29th Jun 20237:00 amRNSAnnual Financial Report
16th Jun 20233:51 pmRNSHolding(s) in Company
2nd Jun 20232:30 pmRNSResults of EGM
26th May 202312:15 pmRNSWarrant Exercise
23rd May 20232:30 pmRNSKibo Subsidiary MED Issue of Shares
22nd May 20233:00 pmRNSKibo Subsidiary Issue of Shares
18th May 20237:00 amRNSMED Update, JV and Reprofiling of Loan Facilities

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.